MAAT MAAT PHARMA SA

MaaT Pharma Announces Participation in Three Upcoming Investor Conferences in September

LYON, France--(BUSINESS WIRE)--

(EURONEXT: MAAT – the “Company”), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today announced that Hervé Affagard, CEO and co-founder of MaaT Pharma, and Siân Crouzet, CFO of MaaT Pharma, will participate in three upcoming investor conferences.

Details for the events are as follow:

H.C. Wainwright 24th Annual Global Investment Conference (hybrid format)

  • Format: virtual presentation & investor meetings
  • Presentation date: Hervé Affagard will present the Company and provide a corporate update.

The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7:00 am EST/1:00 pm CET on Monday, September 12, 2022. A replay will be available on the investor page of Maat Pharma’s website:

  • Link:

KBC Securities Life Sciences conference (virtual)

  • Format: virtual investor meetings
  • Date: Thursday, September 15 and Friday, September 16, 2022

5th edition of the “FORUM Lyon Pôle Bourse Valeurs Régionales” (on-site event)

  • Format: investor meetings
  • Date: Wednesday, September 28, 2022
  • Location: Lyon, France
  • Link:

About MaaT Pharma

MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma launched in March 2022 in Europe, a Phase 3 clinical trial for patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint®, supports the development and expansion of its pipeline by determining novel disease targets, evaluating drug candidates, and identifying biomarkers for microbiome-related conditions. The company’s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice.

MaaT Pharma is the first company developing microbiome-based therapies listed on Euronext Paris (ticker: MAAT).

EN
08/09/2022

Underlying

MAATMAAT PHARMA SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MAAT PHARMA SA

Jacob Mekhael
  • Jacob Mekhael
GLPG GALAPAGOS NV
AUTL Autolus Therape... ... (+3)

EHA abstracts Autolus, Galapagos, MaaT

The abstracts for presentations at EHA (12-15 June) became available yesterday during the day (here). While we may have to wait until the actual conference for the latest datasets, here in this note are some key takeaways for our coverage including updates from Autolus (long-term findings and predictors of sustained remission for Aucatzyl in r/r adult ALL, as well as age stratified outcomes), Galapagos (more data and follow up from its decentralised CAR-T program) and MaaT (additional data from ...

GLPG GALAPAGOS NV
AUTL AUTOLUS THERAPEUTICS ADS
MAAT MAAT PHARMA SA
05/15/25 May 15, 2025 1 EN
Guy Sips ... (+7)
  • Guy Sips
  • Jacob Mekhael
  • Lynn Hautekeete
  • Michiel Declercq
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi
BEKB BEKAERT SA
ABN ABN AMRO Bank N... ... (+9)

Morning Notes : ABN NA, AGFB BB, BEKB BB, COFB BB, DIE BB, SHUR BB, MA...

: ABN NA, AGFB BB, BEKB BB, COFB BB, DIE BB, SHUR BB, MAAT FP, DEME BB, PHVS US

BEKB BEKAERT SA
ABN ABN AMRO BANK NV DEPOSITARY RECEIPTS
COFB COFINIMMO SA
DIE D'IETEREN SA
AGFB AGFA-GEVAERT NV
PHVS PHARVARIS NV
MAAT MAAT PHARMA SA
DEME DEME GROUP NV
SHUR SHURGARD SELF STORAGE LIMITED
05/14/25 May 14, 2025 1 EN
Jacob Mekhael
  • Jacob Mekhael
MAAT MAAT PHARMA SA

MaaT Pharma 1Q25 reiterates pipeline timelines, cash runway into Octob...

MaaT reported 1Q25 results with revenues of € 1.1m (1Q24 € 0.8m), and a cash position of € 24.4m (YE24: € 20.2m), which provides a cash runway into October 2025. Pipeline timelines were reiterated and we look forward to phase 2 data for MaaT013 in combination with immune checkpoint inhibitors in metastatic melanoma in 2H25, and hope to learn more about the company's progress with respect to partnering discussions for MaaT013 in aGvHD in Europe as we approach MAA submission in June 2025. We reite...

05/14/25 May 14, 2025 1 EN
Hilde Van Boxstael ... (+3)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Wim Lewi
05/12/25 May 12, 2025 1 EN
Jacob Mekhael
  • Jacob Mekhael
MAAT MAAT PHARMA SA

MaaT Pharma FIRST LOOK: MaaT033 slows disease progression in phase 1 A...

MaaT reported additional results from the exploratory single arm phase 1b trial of MaaT033 in ALS, and we view the slower disease progression observed with MaaT033 as encouraging, though we also note the small patient numbers and single arm nature of the trial. ALS is a difficult condition, where many drugs have failed to show slowing of disease progression. As such, MaaT033's early results are promising, and the company is seeking partners focussed on ALS to progress this program. We reiterate ...

05/12/25 May 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch